Sources

4 Total Sources

Lilly Reports 70% Response Rates for AJ1-11095 in 23 Myelofibrosis Patients

Center100%
Investors | Eli Lilly and Company1d ago
Lilly to Present Positive Initial Clinical Data for Type II JAK2 Inhibitor AJ1-11095 in Myelofibrosis
StockTitan1d ago
Eli Lilly to present Phase 1 type II JAK2 data at EHA | LLY Stock News
Fierce Biotech1d ago
Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works 'right out of the gate' | Fierce Biotech
AInvest1d ago
Eli Lilly: The JAK2 Inhibitor Data Is Too Small To Change The GLP-1 Story - Hold At 39x